Abstract:
Objective To evaluate the therapeutic effects of ursodeoxycholic acid plus rosuvastatin on patients with fatty liver and hyperlipidemia.
Methods A total of 90 patients were enrolled from October 2021 to September 2024 and randomly allocated into three groups (A, B, and C) using the random number table method. All groups received standard treatment. In addition, Group A received ursodeoxycholic acid, Group B received rosuvastatin, and Group C received a combination of ursodeoxycholic acid and rosuvastatin. Comparative analyses were conducted on liver function indices, lipid profile parameters, symptom severity scores, and clinical efficacy rates across the three groups.
Results The levels of GGT, ALT, AST, TG, TC, and LDL-C in group C were lower than those in groups A and B, and the level of HDL-C was higher than that in groups A and B (P＜0.05). The swelling, discomfort, fatigue, and poor appetite scores in group C were lower than those in groups A and B (P＜0.05). The clinical efficacy in group C was higher than that in groups A and B (P＜0.05).
Conclusion Compared to monotherapy, combination therapy can better improve liver function indicators, blood lipid indicators, and clinical symptoms in patients with fatty liver and hyperlipidemia. Hence, this strategy holds significant clinical promise and merits broader adoption.
Key words:
Ursodeoxycholic acid,
Liver function indicators,
Rosuvastatin,
Blood lipid indicators,
Fatty liver,
Hyperlipidemia
Lingzhi Zhao, Guangying Shi. Clinical efficacy of ursodeoxycholic acid combined with rosuvastatin in treatment of patients with fatty liver complicated with hyperlipidemia[J]. Chinese Journal of Clinicians(Electronic Edition), 2025, 19(08): 589-593.